Emergent BioSolutions Inc. EBS

About Emergent BioSolutions Inc. (EBS): stock profile, AI score and financials

Emergent BioSolutions Inc. (EBS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores EBS at 31.4/100 on a composite quality score built from its SEC filings, placing it at rank #2,435 of 2,925 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (5.2) and profitability (14.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 37.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Emergent BioSolutions Inc. reports quarterly revenue of $234.3M, net income of $-180.2M, an operating margin of -53.4%. Top institutional holders of EBS by reported 13-F value include BlackRock, DIMENSIONAL FUND ADVISORS, STATE STREET, based on the most recent SEC filings. EBS trades on the NYSE exchange and files with the SEC under CIK 1367644. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EBS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Emergent BioSolutions Inc. directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1367644 →